Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure: A Systematic Review and Meta-analysis: Annals of Internal Medicine: Vol 0, No 0

Memberships:

Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Center, MAGIC China Center, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China (XZ, QS, Y. Zhou, HT)

Department of Medicine, Lovisenberg Diaconal Hospital, Oslo, Norway (POV)

Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada (GG, SP)

Division of Molecular and Clinical Medicine, Ninewells Hospital, University of Dundee, Dundee, United Kingdom (CCL)

Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China (SW, Y. Zhu)

Department of Medicine, McMaster University, Hamilton, Ontario, Canada (AA)

Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Daping Hospital, Army Medical University, Chongqing, China (ZZ)

Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Center, MAGIC China Center, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China, and Division of Population Health and Genomics, Ninewells Hospital, University of Dundee, Dundee, United Kingdom (SL).

Grant Support: By grant 2018YFA0800601 from the National Key R&D Program of China, grant 2017YFC0910004 from the National Key Development Plan for Precision Medicine Research, grants 81721001 and 81601012 from the National Natural Science Foundation of China, and grants ZYGD18022 and 20HXFH011 from the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M21-4284.

Reproducible Research Statement:Study protocol: Available at www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=255544. Statistical code and data set: Available from Dr. Li (email, [email protected]com gold [email protected]ed.cn).

Corresponding Author: Sheyu Li, MD, Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Center, MAGIC China Center, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China; E-mail, [email protected]com gold [email protected]ed.cn.

Author Contributions: Conception and design: G. Guyatt, S. Li, H. Tian, ​​PO Vandvik, S. Wang.

Analysis and interpretation of the data: G. Guyatt, CC Lang, S. Li, S. Parpia, Q. Shi, PO Vandvik, S. Wang, Y. Zhu, X. Zou.

Drafting of the article: S. Li, Q. Shi, PO Vandvik, S. Wang, X. Zou.

Critical revision for important intellectual content: A. Agarwal, CC Lang, S. Li, S. Parpia, Q. Shi, PO Vandvik, S. Wang, Y. Zhou, Z. Zhu.

Final approval of the article: A. Agarwal, G. Guyatt, CC Lang, S. Li, S. Parpia, Q. Shi, H. Tian, ​​PO Vandvik, S. Wang, Y. Zhou, Y. Zhu, Z. Zhu, X. Zou.

Statistical expertise: S. Parpia, Q. Shi, PO Vandvik.

Obtaining of funding: S. Li, Z. Zhu.

Administrative, technical, or logistical support: S. Li, PO Vandvik, S. Wang, Y. Zhu.

Collection and assembly of data: S. Li, Q. Shi, S. Wang, X. Zou.

This article was published at Annals.org on 12 April 2022.

* Ms. Xinyu Zou and Mr. Qingyang Shi contributed equally to this work.

Leave a Comment